Merck Acquires Acceleron for $11.5 Billion, Gaining Access to a Phase 3 Cardiovascular Asset
New Jersey-based Merck announced its plan to acquire Acceleron for $11.5 billion ($180 per share) in an all-cash deal that amounts to a whopping 38.5% premium of Acceleron's stock value in September.
The announcement was not unexpected as news trickled through the grapevine last week that a major pharma company is in talks with Acceleron for a potential buyout. On Monday, the Wall Street Journal reported that Merck was the highest bidder, edging out fellow competitors like Bristol Myers Squibb.
The acquisition will let Merck lay its hands on Acceleron's lead cardiovascular candidate, sotatercept, an investigational reverse-remodeling agent proposed to rebalance TGF-beta superfamily signaling in patients with pulmonary arterial hypertension (PAH), a rare, progressive, and life-threatening blood vessel disorder. However, Merck might have to divest its own PAH asset, Adempas, an oral sGC stimulator it gained through a 2014 deal with Bayer, over concerns of market monopoly.
The announcement was not unexpected as news trickled through the grapevine last week that a major pharma company is in talks with Acceleron for a potential buyout. On Monday, the Wall Street Journal reported that Merck was the highest bidder, edging out fellow competitors like Bristol Myers Squibb.
The acquisition will let Merck lay its hands on Acceleron's lead cardiovascular candidate, sotatercept, an investigational reverse-remodeling agent proposed to rebalance TGF-beta superfamily signaling in patients with pulmonary arterial hypertension (PAH), a rare, progressive, and life-threatening blood vessel disorder. However, Merck might have to divest its own PAH asset, Adempas, an oral sGC stimulator it gained through a 2014 deal with Bayer, over concerns of market monopoly.
GO Prime with only $1.49 now
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02